Protection of Cell Therapeutics from Antibody-Mediated Killing by CD64 Overexpression

In three applications of the approach, human CD64t-engineered thyroid epithelial cells, pancreatic beta cells, and CAR T cells withstood clinically relevant levels of graft-directed antibodies and fully evaded antibody-mediated killing.